Ideas take shape to cure many diseases
Dynamics of IDO
Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza
EMC, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C,
Binachi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H,
Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R,
Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F,
Puccetti P. Aryl hydrocarbon receptor control of disease tolerance defence pathway.
Nature 2014; 511-184:90.
Pallotta MT, Fallarino F, Matino D, Macchiarulo A, Orabona C. AhR-Mediated, Non-
Genomic Modulation of IDO1 Function. Front Immunol. 2014; 5, 497.
Volpi C, Mondanelli, G, Puccetti, Grohmann U. TLRs and tryptophan metabolism at the
crossroad of immunoregulatory pathways. Immunometabolism 2014; 1:28-50.
Freely available at: http://www.degruyter.com/view/j/immun.2013.1.issue/immun-2014-
0001/immun-2014-0001.xml
Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, Orabona C, De Luca
A, Boon L, Romani L, Grohmann U, Puccetti P. High doses of CpG oligodeoxynucleotides
stimulate a tolerogenic TLR9–TRIF pathway. Nat Commun 2013; 4:1852.
Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci
C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P,
Grohmann U. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance
by dendritic cells. Nat Immunol 2011; 12:870-8.
Grohmann U, Bronte V. Control of immune response by amino acid metabolism. Immunol
Rev 2010; 236:243-64.
Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan
catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-
dioxygenase (IDO), a novel target in cancer disease. Amino Acids. 2009; 37(2), 219-229.
Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L,
Grohmann U. IDO mediates TLR9-driven protection from experimental autoimmune
diabetes. J Immunol 2009; 183:6303-13.
Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S,
Fioretti MC, Grohmann U, Puccetti P. Cutting edge: Autocrine TGF-β sustains default
tolerogenesis by IDO-competent dendritic cells. J Immunol 2008; 181;5194-5198.
Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti
MC, Grohmann U, Puccetti P. SOCS3 drives proteasomal degradation of indoleamine 2,3-
dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci
USA 2008; 105:20828-33.
Macchiarulo A, Nuti R, Bellocchi D, Camaioni E, Pellicciari R. Molecular docking and spatial
coarse graining simulations as tools to investigate substrate recognition, enhancer
binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO). Biochim
Biophys Acta. 2007; 1774(8), 1058-1068.
Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna
ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti
P. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in
allergy. Nat Med 2007; 13:579-586.
Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F, Bianchi R, Velardi E,
Perruccio K, Velardi A, Bronte V, Fioretti MC, Grohmann U. Toward the identification of a
tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107:2846-2854.
Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi
S, Salomon BL, Fioretti MC, Romani L, Puccetti P. CD28 induces immunostimulatory
signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5:1134-1142.
Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P. A defect
in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003;
198:153-160.
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML,
Fioretti MC, Alegre M-L, Puccetti P. Modulation of tryptophan catabolism by regulatory T
cells. Nat Immunol 2003; 4:1206-1212.
Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P,
Belladonna ML, Bianchi R, Fioretti MC, Puccetti P. CTLA-4Ig regulates tryptophan
catabolism in vivo. Nat Immunol 2002; 3:1097-1101.
Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C, Uyttenhove C,
Fioretti MC, Puccetti P. IL-6 inhibits the tolerogenic function of CD8α+ dendritic cells
expressing indoleamine 2,3-dioxygenase. J Immunol 2001; 167:708-714.
EMC, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C,
Binachi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H,
Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R,
Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F,
Puccetti P. Aryl hydrocarbon receptor control of disease tolerance defence pathway.
Nature 2014; 511-184:90.
Pallotta MT, Fallarino F, Matino D, Macchiarulo A, Orabona C. AhR-Mediated, Non-
Genomic Modulation of IDO1 Function. Front Immunol. 2014; 5, 497.
Volpi C, Mondanelli, G, Puccetti, Grohmann U. TLRs and tryptophan metabolism at the
crossroad of immunoregulatory pathways. Immunometabolism 2014; 1:28-50.
Freely available at: http://www.degruyter.com/view/j/immun.2013.1.issue/immun-2014-
0001/immun-2014-0001.xml
Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, Orabona C, De Luca
A, Boon L, Romani L, Grohmann U, Puccetti P. High doses of CpG oligodeoxynucleotides
stimulate a tolerogenic TLR9–TRIF pathway. Nat Commun 2013; 4:1852.
Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci
C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P,
Grohmann U. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance
by dendritic cells. Nat Immunol 2011; 12:870-8.
Grohmann U, Bronte V. Control of immune response by amino acid metabolism. Immunol
Rev 2010; 236:243-64.
Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan
catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-
dioxygenase (IDO), a novel target in cancer disease. Amino Acids. 2009; 37(2), 219-229.
Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L,
Grohmann U. IDO mediates TLR9-driven protection from experimental autoimmune
diabetes. J Immunol 2009; 183:6303-13.
Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S,
Fioretti MC, Grohmann U, Puccetti P. Cutting edge: Autocrine TGF-β sustains default
tolerogenesis by IDO-competent dendritic cells. J Immunol 2008; 181;5194-5198.
Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti
MC, Grohmann U, Puccetti P. SOCS3 drives proteasomal degradation of indoleamine 2,3-
dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci
USA 2008; 105:20828-33.
Macchiarulo A, Nuti R, Bellocchi D, Camaioni E, Pellicciari R. Molecular docking and spatial
coarse graining simulations as tools to investigate substrate recognition, enhancer
binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO). Biochim
Biophys Acta. 2007; 1774(8), 1058-1068.
Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna
ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti
P. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in
allergy. Nat Med 2007; 13:579-586.
Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F, Bianchi R, Velardi E,
Perruccio K, Velardi A, Bronte V, Fioretti MC, Grohmann U. Toward the identification of a
tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107:2846-2854.
Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi
S, Salomon BL, Fioretti MC, Romani L, Puccetti P. CD28 induces immunostimulatory
signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5:1134-1142.
Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P. A defect
in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003;
198:153-160.
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML,
Fioretti MC, Alegre M-L, Puccetti P. Modulation of tryptophan catabolism by regulatory T
cells. Nat Immunol 2003; 4:1206-1212.
Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P,
Belladonna ML, Bianchi R, Fioretti MC, Puccetti P. CTLA-4Ig regulates tryptophan
catabolism in vivo. Nat Immunol 2002; 3:1097-1101.
Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C, Uyttenhove C,
Fioretti MC, Puccetti P. IL-6 inhibits the tolerogenic function of CD8α+ dendritic cells
expressing indoleamine 2,3-dioxygenase. J Immunol 2001; 167:708-714.
